Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate


Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being conducted after discussions with the FDA and is effec (US Food Recalls) More More

Similar stories

Lawmakers Seek Clarity From FDA on Recall of Lifesaving Drug - Regulatory Focus

Lawmakers Seek Clarity From FDA on Recall of Lifesaving Drug  Regulatory Focus

Posted on 18 October 2019 | 2:00 am | Google News

Takeda recalls parathyroid hormone injection for potential rubber contamination - Healio

Takeda recalls parathyroid hormone injection for potential rubber contamination  Healio

Posted on 17 September 2019 | 2:00 am | Google News

Takeda issues recall of Natpara - BioPharma-Reporter.com

Takeda issues recall of Natpara  BioPharma-Reporter.com

Posted on 10 September 2019 | 2:00 am | Google News

Takeda issues US recall of NATPARA, a parathyroid hormone - BSA bureau

Takeda issues US recall of NATPARA, a parathyroid hormone  BSA bureau

Posted on 9 September 2019 | 2:00 am | Google News

Particulate issues cause Takeda US recall of Natpara - The Pharma Letter

Particulate issues cause Takeda US recall of Natpara  The Pharma Letter

Posted on 6 September 2019 | 2:00 am | Google News

Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate - PRNewswire

Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate  PRNewswire

Posted on 5 September 2019 | 2:00 am | Google News

Copyright © 2020 LastMinuteStuff.com | Contact info